Superior Near-IR Dyes for Bioimaging

用于生物成像的优质近红外染料

基本信息

项目摘要

Optical imaging is an advanced technique to image biotechnology products like gels, sensors, and micro arrays. It is also used increasingly to monitor specific molecular pathways in animals. This latter technique uses fluorescent dyes that absorb and emit near-infrared (NIR) radiation (650-900 nm) a spectral window where hemoglobin and water absorb minimally and therefore allow photons to penetrate several centimeters through tissue. This proposal builds on our recent discovery that squaraine rotaxanes (SRs) are among the world's brightest and most stable fluorescent NIR dyes. However due to their poor solubility under aqueous conditions, their usefulness in biological applications remains a challenge thus limiting their commercial appeal. Our plan is therefore to improve dye performance by introducing water solublizing sulfonate or phosphonic acid groups into the molecular structure. With further development, they are likely to become superior replacements for the popular cyanine (Cy5) dyes and become extremely useful probes for both in vitro and in vivo imaging applications. The overall goal for Phase I is to prepare novel water soluble SR dyes and compare the properties of various bioconjugates that have been labeled with SR or Cy5. The two Specific Aims of the present proposal are: 1) SA1 to be performed at MTTI - Synthesize novel water soluble SR NHS esters incorporating multiple sulfonate or phosphonic acid groups and conjugate to 3 different types of biomolecules, an antibody, a protein and a vitamin for comparison with Cy5 analogues. The first goal is to produce water soluble squaraine rotaxane probes having sulfonate or phosphonic acid groups. This will be followed by conjugation of the squaraine rotaxane probes as well as Cy5 as control probe to IgG protein, streptavidin and a folic acid derivative. 2) SA2 to be perfomed at UND - In vitro and in vivo evaluation of bioconjugates. In vitro molecular recognition performance of the SR and Cy5 fluorescent IgG and streptavidin bioconjugates developed at MTTI will be characterized using standard gel electrophoresis and streptavidin/biotin protocols. In vitro and In vivo molecular recognition performance of fluorescent SR and Cy5 folate conjugates will be determined using cultured cells that express high levels of the folate receptor and in whole animal imaging studies of murine xenograft tumor models. The goal is to demonstrate the advantage of using molecular probes labeled with SR dyes in 3 different systems compared with Cy dyes. PA-08-050
光学成像是对凝胶、传感器和微阵列等生物技术产品进行成像的先进技术。它也越来越多地用于监测动物的特定分子途径。后一种技术使用荧光染料吸收并发射近红外(NIR)辐射(650-900纳米),这是血红蛋白和水吸收最小的光谱窗口,因此允许光子穿透组织几厘米。我们最近发现,方烷轮烷(SRs)是世界上最亮、最稳定的近红外荧光染料之一。然而,由于它们在水条件下的溶解度差,它们在生物应用中的实用性仍然是一个挑战,从而限制了它们的商业吸引力。因此,我们的计划是通过在分子结构中引入水溶性磺酸或膦酸基团来改善染料的性能。随着进一步的发展,它们很可能成为流行的花青素(Cy5)染料的优良替代品,并成为在体外和体内成像应用中非常有用的探针。第一阶段的总体目标是制备新型水溶性SR染料,并比较用SR或Cy5标记的各种生物偶联物的性能。本提案的两个具体目标是:1)在MTTI进行SA1 -合成含有多个磺酸或膦酸基团的新型水溶性SR NHS酯,并结合3种不同类型的生物分子,抗体,蛋白质和维生素,以与Cy5类似物进行比较。第一个目标是生产具有磺酸或膦酸基团的水溶性方胺轮烷探针。随后将squaraine rotaxane探针以及Cy5作为对照探针与IgG蛋白、链亲和素和叶酸衍生物偶联。2) SA2将在UND上进行-生物偶联物的体外和体内评价。MTTI开发的SR和Cy5荧光IgG和链霉亲和素生物偶联物的体外分子识别性能将采用标准凝胶电泳和链霉亲和素/生物素方案进行表征。荧光SR和Cy5叶酸偶联物的体外和体内分子识别性能将通过表达高水平叶酸受体的培养细胞和小鼠异种移植肿瘤模型的全动物成像研究来确定。目的是证明与Cy染料相比,在3种不同的系统中使用SR染料标记的分子探针的优势。pa - 08 - 050

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brian David Gray其他文献

Brian David Gray的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brian David Gray', 18)}}的其他基金

Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk
磷脂酰丝氨酸阻断纳米颗粒可改善抗血栓形成并降低出血风险
  • 批准号:
    10598788
  • 财政年份:
    2023
  • 资助金额:
    $ 17.68万
  • 项目类别:
Instantaneous Tumor Spray for Real-Time Surgical Guidance
用于实时手术指导的瞬时肿瘤喷雾
  • 批准号:
    10681383
  • 财政年份:
    2022
  • 资助金额:
    $ 17.68万
  • 项目类别:
Instantaneous Tumor Spray for Real-Time Surgical Guidance
用于实时手术指导的瞬时肿瘤喷雾
  • 批准号:
    10543617
  • 财政年份:
    2022
  • 资助金额:
    $ 17.68万
  • 项目类别:
Topical Drug Treatment of Cutaneous Leishmaniasis
皮肤利什曼病的局部药物治疗
  • 批准号:
    9383791
  • 财政年份:
    2017
  • 资助金额:
    $ 17.68万
  • 项目类别:
Multicolor Cell Membrane Profiling For Development And Disease
发育和疾病的多色细胞膜分析
  • 批准号:
    8589954
  • 财政年份:
    2013
  • 资助金额:
    $ 17.68万
  • 项目类别:
Anionic Phospholipid-Selective PET/SPECT Agent for Infection Imaging
用于感染成像的阴离子磷脂选择性 PET/SPECT 试剂
  • 批准号:
    8250164
  • 财政年份:
    2012
  • 资助金额:
    $ 17.68万
  • 项目类别:
Dual Modality Labels for Macro and Micro Detection and Quantification of Stem Cel
用于干细胞宏观和微观检测及定量的双模态标签
  • 批准号:
    7909750
  • 财政年份:
    2010
  • 资助金额:
    $ 17.68万
  • 项目类别:
Radiohybridization Imaging of HER2 Oncogene to Detect Breast Cancer
HER2 癌基因放射杂交成像检测乳腺癌
  • 批准号:
    7681555
  • 财政年份:
    2008
  • 资助金额:
    $ 17.68万
  • 项目类别:
Radiohybridization Imaging of HER2 Oncogene to Detect Breast Cancer
HER2 癌基因放射杂交成像检测乳腺癌
  • 批准号:
    7536308
  • 财政年份:
    2008
  • 资助金额:
    $ 17.68万
  • 项目类别:
Optimizing Tracers For Multicolor Neuronal Profiling
优化多色神经元分析示踪剂
  • 批准号:
    7418498
  • 财政年份:
    2004
  • 资助金额:
    $ 17.68万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了